A Randomized Phase II Trial of Combined Nivolumab and Ipilimumab with or without Stereotactic Body Radiation Therapy for Advanced Merkel Cell Carcinoma

Saved in:

Bibliographic Details
Published in	The Lancet (British edition) Vol. 400; no. 10357; pp. 1008 - 1019
Main Authors	Kim, Sungjune, Wuthrick, Evan, Blakaj, Dukagjin, Eroglu, Zeynep, Verschraegen, Claire, Thapa, Ram, Mills, Matthew, Dibs, Khaled, Liveringhouse, Casey, Russell, Jeffery, Caudell, Jimmy J., Tarhini, Ahmad, Markowitz, Joseph, Kendra, Kari, Wu, Richard, Chen, Dung-Tsa, Berglund, Anders, Michael, Lauren, Aoki, Mia, Wang, Min-Hsuan, Hamaidi, Imene, Cheng, Pingyan, de la Iglesia, Janis, Slebos, Robbert J., Chung, Christine H., Knepper, Todd C., Moran-Segura, Carlos M., Nguyen, Jonathan V., Perez, Bradford, Rose, Trevor, Harrison, Louis, Messina, Jane L., Sondak, Vernon K., Tsai, Kenneth Y., Khushalani, Nikhil I., Brohl, Andrew S.
Format	Journal Article
Language	English
Published	12.09.2022
Online Access	Get full text

Loading…

More Information
Bibliography:	All authors analyzed and interpreted the data, wrote the manuscript, and approved the final version of the manuscript. SK and JR conceived and designed the study. SK, EW, DB, ZE, CV, JR, JC, AT, JM, KK, RW, NK, and AB accrued patients on the study. SK, RT, MM, KD, CL, DTC, LM, BP and AB collected and assembled the data. Authors' contributions
ISSN:	0140-6736 1474-547X
DOI:	10.1016/S0140-6736(22)01659-2